Tanuja Chitnis

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi request reprint Inflammatory demyelinating diseases in children: an update
    C Fernández Carbonell
    Department of Child Neurology, Massachusetts General Hospital, Boston, MA, USA
    Minerva Pediatr 65:307-23. 2013
  2. doi request reprint Pediatric multiple sclerosis: Escalation and emerging treatments
    Tanuja Chitnis
    From Partners Pediatric MS Center T C, Massachusetts General Hospital, Harvard Medical School, Boston Divisione di Neurologia 2 Centro Studi Sclerosi Multipla A G, Ospedale di Gallarate, Italy Department of Neurology B B K, Medical University of Vienna, Austria Department of Neurology, Neurosurgery and Medical Genetics A B, Pirogov s Russian National Research Medical University, Moscow Barts and The London School of Medicine and Dentistry G G, London, UK and Department of Neurology D P, Children s Hospital of Eastern Ontario, University of Ottawa, Canada
    Neurology 87:S103-9. 2016
  3. doi request reprint Role of puberty in multiple sclerosis risk and course
    Tanuja Chitnis
    Partners Pediatric Multiple Sclerosis Center, Department of Child Neurology, Massachusetts General Hospital, Boston, MA, USA Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA, USA Electronic address
    Clin Immunol 149:192-200. 2013
  4. doi request reprint Pediatric demyelinating diseases
    Tanuja Chitnis
    Massachusetts General Hospital, Department of Child Neurology, Boston, MA 02114, USA
    Continuum (Minneap Minn) 19:1023-45. 2013
  5. pmc International Pediatric MS Study Group Clinical Trials Summit: meeting report
    Tanuja Chitnis
    Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, Boston, MA, USA
    Neurology 80:1161-8. 2013
  6. pmc Disease-modifying therapy of pediatric multiple sclerosis
    Tanuja Chitnis
    Harvard Medical School, Boston, MA 02115, USA
    Neurotherapeutics 10:89-96. 2013
  7. doi request reprint Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis
    T Chitnis
    Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Mult Scler 18:116-27. 2012
  8. ncbi request reprint Pediatric multiple sclerosis
    Tanuja Chitnis
    Brigham and Women s Hospital, Massachusetts General Hospital for Children, Harvard Medical School, Boston, Massachusetts 02115, USA
    Neurologist 12:299-310. 2006
  9. doi request reprint Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States
    T Chitnis
    Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital for Children, Boston, MA, USA Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Boston, MA, USA
    Mult Scler 15:627-31. 2009
  10. pmc No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50
    Riley Bove
    Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital, Brookline, MA 02445, USA
    BMC Neurol 13:73. 2013

Collaborators

Detail Information

Publications83

  1. ncbi request reprint Inflammatory demyelinating diseases in children: an update
    C Fernández Carbonell
    Department of Child Neurology, Massachusetts General Hospital, Boston, MA, USA
    Minerva Pediatr 65:307-23. 2013
    ..We also review new research advances including novel biomarkers and treatments from the latest literature...
  2. doi request reprint Pediatric multiple sclerosis: Escalation and emerging treatments
    Tanuja Chitnis
    From Partners Pediatric MS Center T C, Massachusetts General Hospital, Harvard Medical School, Boston Divisione di Neurologia 2 Centro Studi Sclerosi Multipla A G, Ospedale di Gallarate, Italy Department of Neurology B B K, Medical University of Vienna, Austria Department of Neurology, Neurosurgery and Medical Genetics A B, Pirogov s Russian National Research Medical University, Moscow Barts and The London School of Medicine and Dentistry G G, London, UK and Department of Neurology D P, Children s Hospital of Eastern Ontario, University of Ottawa, Canada
    Neurology 87:S103-9. 2016
    ..In addition, ongoing clinical trials and approaches and challenges in conducting clinical trials in the pediatric population are discussed. ..
  3. doi request reprint Role of puberty in multiple sclerosis risk and course
    Tanuja Chitnis
    Partners Pediatric Multiple Sclerosis Center, Department of Child Neurology, Massachusetts General Hospital, Boston, MA, USA Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA, USA Electronic address
    Clin Immunol 149:192-200. 2013
    ..Reviewed is the relationship of MS risk factors and puberty, and differences in disease presentation of pre- and post-pubertal children with MS. Further avenues of research are discussed. ..
  4. doi request reprint Pediatric demyelinating diseases
    Tanuja Chitnis
    Massachusetts General Hospital, Department of Child Neurology, Boston, MA 02114, USA
    Continuum (Minneap Minn) 19:1023-45. 2013
    ..This review summarizes the current knowledge on monophasic and chronic demyelinating disorders in children, focusing on an approach to diagnosis and management...
  5. pmc International Pediatric MS Study Group Clinical Trials Summit: meeting report
    Tanuja Chitnis
    Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, Boston, MA, USA
    Neurology 80:1161-8. 2013
    ..The goal of this meeting was to assess areas of consensus regarding clinical trial design and outcome measures among academic experts involved in pediatric MS care and research...
  6. pmc Disease-modifying therapy of pediatric multiple sclerosis
    Tanuja Chitnis
    Harvard Medical School, Boston, MA 02115, USA
    Neurotherapeutics 10:89-96. 2013
    ....
  7. doi request reprint Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis
    T Chitnis
    Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Mult Scler 18:116-27. 2012
    ..Mechanisms for conducting high-impact, multicenter studies, including long-term follow-up in pediatric MS, are required to ensure that all MS patients, irrespective of age, benefit from advances in MS therapeutics...
  8. ncbi request reprint Pediatric multiple sclerosis
    Tanuja Chitnis
    Brigham and Women s Hospital, Massachusetts General Hospital for Children, Harvard Medical School, Boston, Massachusetts 02115, USA
    Neurologist 12:299-310. 2006
    ....
  9. doi request reprint Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States
    T Chitnis
    Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital for Children, Boston, MA, USA Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Boston, MA, USA
    Mult Scler 15:627-31. 2009
    ..The prevalence of pediatric-onset multiple sclerosis (MS) in the United States is unknown...
  10. pmc No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50
    Riley Bove
    Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital, Brookline, MA 02445, USA
    BMC Neurol 13:73. 2013
    ..Little is known about sex-specific changes in disease course around age 50, which may represent a key biological transition period for reproductive aging...
  11. ncbi request reprint Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis
    Bing Zhu
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 176:3480-9. 2006
    ..In conclusion, PD-L1 and PD-L2 differentially regulate the susceptibility and chronic progression of EAE in a strain-specific manner...
  12. pmc Clinical and MRI phenotype of children with MOG antibodies
    Cristina Fernandez-Carbonell
    Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA, USA
    Mult Scler 22:174-84. 2016
    ..To investigate the clinical and magnetic resonance imaging (MRI) features of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-seropositive pediatric demyelinating syndromes...
  13. pmc Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis
    Katherine A McLaughlin
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Immunol 183:4067-76. 2009
    ..7% of patients in the 10- to 18-year age group. B cell autoimmunity to this myelin surface Ag is therefore most common in patients with a very early onset of MS...
  14. pmc Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis
    Muhammad Taimur Malik
    From the Partners Multiple Sclerosis Center M T M, B C H, L A B, A M, H L W, T C and Center for Neurological Diseases P K, H L W, T C, Brigham and Women s Hospital, Harvard Medical School, Boston Department of Neurology L A B, Boston Children s Hospital and Partners Pediatric Multiple Sclerosis Center L A B, T C, Massachusetts General Hospital, Boston
    Neurology 82:2173-9. 2014
    ..To identify clinical and demographic features associated with the severity and recovery from acute optic neuritis (AON) episodes in patients with multiple sclerosis (MS)...
  15. pmc Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus
    Linda Ottoboni
    From the Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Departments of Neurology and Psychiatry L O, I Y F, M L, B T K, Z X, P L D, Department of Neurology, Partners MS Center, Center for Neurologic Diseases B C H, T C, S J K, H L W, P L D, and Center for Neurological Imaging, Department of Radiology C R G, Brigham and Women s Hospital and Harvard Medical School, Boston, MA Program in Medical and Population Genetics L O, I Y F, M L, B T K, Z X, P L D, Broad Institute of Harvard University and the Massachusetts Institute of Technology, Cambridge and the Department of Neurology and Immunobiology D A H, Yale School of Medicine, New Haven, CT
    Neurology 81:1891-9. 2013
    ..We set out to characterize the clinical impact and functional consequences of rs1800693(G), the multiple sclerosis (MS) susceptibility allele found in the TNFRSF1A locus...
  16. pmc Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration
    Tanuja Chitnis
    Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Pathol 170:1695-712. 2007
    ..Strategies that up-regulate the expression of CD200 in the CNS or molecules that ligate the CD200R may be relevant as neuroprotective strategies in multiple sclerosis...
  17. doi request reprint Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life
    Bonnie I Glanz
    Department of Neurology, Harvard Medical School, Boston, MA, USA
    Value Health 15:1029-35. 2012
    ....
  18. doi request reprint Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis
    Brian C Healy
    Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Harvard Medical School, Brookline, MA 02115, USA
    J Neurol Sci 303:109-13. 2011
    ..DMT modeling choice had a modest impact on the variables classified as predictors of EDSS score change. Importantly, however, interpretation of these predictors is dependent upon modeling choice...
  19. pmc The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis
    Vinit V Oommen
    Department of Neurology, Brigham and Women s Hospital, Partners MS Center, Harvard Medical School, Boston, MA
    J Neuroimaging 26:184-7. 2016
    ..We investigated the effect of fingolimod on the evolution of acute gadolinium-enhancing (Gd+) brain lesions to CBH in patients with MS...
  20. doi request reprint Increased Th17 response to myelin peptides in pediatric MS
    David Vargas-Lowy
    Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA, USA
    Clin Immunol 146:176-84. 2013
    ..In addition, T cells with a central memory phenotype producing IL-17 were increased in PMS compared to PHC (p<0.05). IL-7 levels in culture supernatants were elevated in PMS compared to PHC and AMS (t test<0.01)...
  21. pmc Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis
    Keren Regev
    Ann Romney Center for Neurologic Diseases K R, A P, B H, F v G, M A M, R R, P K, T C, H L W, R G, and Partners MS Center C D C, T G, p n, B I G, T C, H L W, Brigham and Women s Hospital, Harvard Medical School, Boston and Biostatistics Center B H, Massachusetts General Hospital, Boston
    Neurol Neuroimmunol Neuroinflamm 3:e267. 2016
    ..To identify circulating microRNAs (miRNAs) linked to disease stage and disability in multiple sclerosis (MS)...
  22. doi request reprint Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis
    Alicia S Chua
    Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Boston, MA, USA
    Neuroimage 119:81-8. 2015
    ..We believe that our findings provide important insights for efficient correction of automated MRI measures to obviate the need to perform manual correction on all cases. ..
  23. doi request reprint Circulating microRNAs as biomarkers for disease staging in multiple sclerosis
    Roopali Gandhi
    Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA
    Ann Neurol 73:729-40. 2013
    ..In MS, a major challenge is to develop immune biomarkers to monitor disease. We asked whether circulating miRNAs could be identified in MS and whether they are linked to disease stage and/or disability...
  24. pmc CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis
    Yingru Liu
    Center for Neurologic Diseases, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 30:2025-38. 2010
    ....
  25. doi request reprint One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis
    Maria Liguori
    Department of Radiology, Center for Neurological Imaging, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurol Neurosurg Psychiatry 82:1125-31. 2011
    ..To compare sensitivity of sMRI and contrast enhanced MRI towards disease activity...
  26. doi request reprint Cognitive and patient-reported outcomes in adults with pediatric-onset multiple sclerosis
    Natalie F Baruch
    Partners Multiple Sclerosis Center, Brigham and Women s Hospital, USA
    Mult Scler 22:354-61. 2016
    ..Little is known about long-term cognitive and patient-reported outcomes of pediatric-onset multiple sclerosis (POMS)...
  27. doi request reprint International Pediatric MS Study Group Global Members Symposium report
    Evangeline Wassmer
    From the Department of Neurology E Wassmer, Birmingham Children s Hospital, UK Partners Pediatric MS Center T C, Massachusetts General Hospital, Harvard Medical School, Boston Department of Neurology D P, Children s Hospital of Eastern Ontario, University of Ottawa, Canada Department NEUROFARBA M P A, Section Neurosciences, University of Florence, Italy Division of Neurology A W, Perelman School of Medicine B B, The Children s Hospital of Philadelphia, University of Pennsylvania Divisione di Neurologia 2 Centro Studi Sclerosi Multipla A G, Ospedale di Gallarate, Italy Department of Neurology R Q H, MS Centre ErasMS, Erasmus MC, Rotterdam, the Netherlands Lourie Center for Pediatric MS L B K, Stony Brook Children s, Stony Brook University, NY Departments of Pediatrics and Neurology N M, Yale University School of Medicine, New Haven, CT Department of Pediatric Neurology K R, Children s Hospital Datteln, University Witten Herdecke, Germany National Reference Center for Inflammatory Diseases of the Brain M T, Hôpitaux Universitaires Paris Sud, University Paris Sud, France Department of Neurology S T, National Pediatric Hospital Dr Juan P Garrahan, Ciudad de Buenos Aires, Argentina Pediatric MS Center E Waubant, Kanagawa 226-8501
    Neurology 87:S110-6. 2016
    ..Of critical importance, clinical trials of newer MS agents in children are required. Although our understanding of childhood MS has improved, further research is needed to have a positive impact for children and their families. ..
  28. pmc Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course
    Riley Bove
    Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Institute for the Neurosciences, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 8:e59707. 2013
    ..com (PLM), for research in multiple sclerosis (MS). An investigation of the role of body mass index (BMI) on MS disease course was conducted to illustrate the utility of the platform...
  29. doi request reprint Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments
    Robert Gross
    Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA, United States
    J Neuroimmunol 233:168-74. 2011
    ..The HLA DRB1 1501 allele explained some of this variation in event-free survival while on GA, and we found suggestive evidence that an IRF8 polymorphism influences event-free survival in IFN β treated subjects...
  30. doi request reprint Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis
    Mark P Gorman
    Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Boston, MA, USA
    Arch Neurol 66:54-9. 2009
    ..To investigate whether or not the disparity in disease progression in those with pediatric-onset compared with adult-onset multiple sclerosis (MS) is due to differences in relapse rates...
  31. pmc Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis
    Wassim Elyaman
    Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Pathol 173:411-22. 2008
    ..Our data extend the understanding of the pathogenicity of autoreactive memory T cells and have important implications for the development of novel therapies for human autoimmune diseases...
  32. doi request reprint The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis
    Brian C Healy
    Partners Multiple Sclerosis Center, Brigham and Women s Hospital, 6th Floor, 1 Brookline Place, Brookline, MA 02445, USA
    Qual Life Res 21:1677-84. 2012
    ..In this study, we estimate the impact of a recent relapse on physical and mental health in subjects with relapsing-remitting multiple sclerosis (RRMS) using validated patient-reported outcome (PRO) measures...
  33. doi request reprint Cognitive deterioration in patients with early multiple sclerosis: a 5-year study
    Bonnie I Glanz
    Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    J Neurol Neurosurg Psychiatry 83:38-43. 2012
    ..Methodological issues associated with longitudinal cognitive research such as practice effects and drop-outs were also examined...
  34. pmc Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models
    Alicia S Chua
    Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Boston, MA, USA
    Neuroimage Clin 8:606-10. 2015
    ....
  35. pmc Modeling disease severity in multiple sclerosis using electronic health records
    Zongqi Xia
    Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts, United States of America Harvard Medical School, Boston, Massachusetts, United States of America Program in Medical and Population Genetics, Broad Institute, Cambridge, Massachusetts, United States of America
    PLoS ONE 8:e78927. 2013
    ....
  36. doi request reprint Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development
    Pia Kivisakk
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Mult Scler 20:438-44. 2014
    ..Osteopontin (OPN) is a pleiotropic protein with important roles in inflammation and immunity that has been suggested as a candidate biomarker for disease activity in multiple sclerosis (MS)...
  37. ncbi request reprint Effect of gender on late-onset multiple sclerosis
    Riley M Bove
    Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Boston, USA
    Mult Scler 18:1472-9. 2012
    ....
  38. pmc Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study
    Jennifer Moodie
    Department of Neurology, University of Massachusetts, Boston, MA, USA
    J Neurol Sci 315:49-54. 2012
    ..We previously described a composite MRI scale combining T1-lesions, T2-lesions and whole brain atrophy in multiple sclerosis (MS): the magnetic resonance disease severity scale (MRDSS)...
  39. pmc Gestational vitamin D and the risk of multiple sclerosis in offspring
    Fariba Mirzaei
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Ann Neurol 70:30-40. 2011
    ..Vitamin D may have a protective role in the etiology of multiple sclerosis (MS), but the effect of gestational vitamin D on adult onset MS has not been studied...
  40. doi request reprint Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies
    Brian Healy
    Partners MS Center, Brigham and Women s Hospital, Brookline, MA 02445, USA
    J Neurol 258:1812-9. 2011
    ..Sustained progression on the EDSS is a less powerful outcome measure for clinical progression than approaches based on the actual EDSS values...
  41. doi request reprint Sample size requirements for one-year treatment effects using deep gray matter volume from 3T MRI in progressive forms of multiple sclerosis
    Gloria Kim
    a Departments of Neurologya and Radiology, Laboratory for Neuroimaging Research, Partners MS Center, Harvard Medical School, Boston, MA, USA
    Int J Neurosci . 2017
    ..This patient population is the target of active neurotherapeutic development, requiring the availability of outcome measures. We tested a fully automated MRI analysis pipeline to assess DGM atrophy in PMS...
  42. pmc Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort
    Riley Bove
    Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital, Brookline, MA, USA Harvard Medical School, Boston, MA, USA Center for Neurologic Diseases, Harvard Medical School, Boston, MA, USA
    Mult Scler 22:935-43. 2016
    ..The impact, if any, of menopause on the MS course is unknown. Our objective was to determine whether menopause is associated with changes in MS severity in a longitudinal clinical cohort...
  43. pmc Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset
    Riley Bove
    Department of Neurology R B, A S C, Z X, P L D J, T C, Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Brookline, MA and Ann Romney Center for Neurologic Diseases R B, A S C, Z X, L C, P L D J, T C, Harvard Medical School R B, Z X, L C, P L D J, T C, Boston, MA
    Neurol Genet 2:e88. 2016
    ..To examine the relationship between 2 markers of early multiple sclerosis (MS) onset, 1 genetic (HLA-DRB1*1501) and 1 experiential (early menarche), in 2 cohorts...
  44. pmc Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis
    Shahamat Tauhid
    Laboratory for Neuroimaging Research, Department of Neurology, Partners MS Center, Harvard Medical School, Brigham and Women s Hospital, Boston, MA, USA
    J Neurol 262:2425-32. 2015
    ..05). We report a link between brain atrophy and lesions, particularly lesions with destructive potential, to MS employment status...
  45. doi request reprint Pediatric multiple sclerosis
    Tanuja Chitnis
    Harvard Medical School, Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital for Children, 55 Fruit Street, Boston, MA 02114, USA
    Neurol Clin 29:481-505. 2011
    ..However, there remain several key areas that require further exploration. This article summarizes the current state of knowledge on pediatric MS and discusses future avenues of investigation...
  46. pmc Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein
    Kevin C O'Connor
    Center for Neurologic Diseases, Brigham and Women s Hospital, 77 Avenue Louis Pasteur, Boston, Massachusetts 02115, USA
    Nat Med 13:211-7. 2007
    ..MOG-specific autoantibodies were identified in a subset of ADEM but only rarely in adult-onset MS cases, indicating that MOG is a more prominent target antigen in ADEM than MS...
  47. ncbi request reprint Cytokines in multiple sclerosis: from bench to bedside
    Jaime Imitola
    Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, 77 Avenue Louis Pasteur, Rm 710, Boston, MA 02115, USA
    Pharmacol Ther 106:163-77. 2005
    ..In this review, we will summarize the current knowledge on the role of cytokine pathways in MS and what we learned from investigation of its animal model: experimental autoimmune encephalomyelitis (EAE)...
  48. pmc Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice
    Jaime Imitola
    Brigham and Women s Hospital, Center for Neurologic Diseases, Partner Multiple Sclerosis Center, Harvard Medical School, Department of Neurology, Boston, Massachusetts 02115, USA
    J Biomed Opt 16:021109. 2011
    ....
  49. ncbi request reprint Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo
    Tanuja Chitnis
    Center for Neurologic Diseases, Laboratory of Immunogenetics and Transplantation, Brigham and Women s Hospital, Harvard School of Public Health, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 172:4260-5. 2004
    ..These data have implications for the treatment of immune-mediated diseases by immunomodulatory agents that alter the cytokine milieu in vivo...
  50. doi request reprint A method for evaluating treatment switching criteria in multiple sclerosis
    Brian C Healy
    Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Mult Scler 16:1483-9. 2010
    ..We investigated a method to evaluate a treatment switching approach, namely treatment change after one multiple sclerosis (MS) relapse...
  51. ncbi request reprint The role of CD4 T cells in the pathogenesis of multiple sclerosis
    Tanuja Chitnis
    Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Int Rev Neurobiol 79:43-72. 2007
    ..Here, we outline basic concepts in CD4+ T-cell immunology and summarize the current understanding of the role of CD4+ T cells in the pathogenesis of MS...
  52. doi request reprint Pathogenesis of pediatric multiple sclerosis
    David Vargas-Lowy
    Center for Neurological Diseases, Department of Neurology, Brigham and Women s Hospital, Boston, MA 02114, USA
    J Child Neurol 27:1394-407. 2012
    ....
  53. pmc Dietary intake of vitamin D during adolescence and risk of multiple sclerosis
    Kassandra L Munger
    Department of Nutrition, Harvard School of Public Health, 665 Huntington Ave, Bldg 2, 3rd Fl, Boston, MA 02115, USA
    J Neurol 258:479-85. 2011
    ..11), whereas intake of whole milk, an important source of dietary vitamin D, was associated with an increased risk. The possibility of opposite effects of vitamin D and milk intake on MS risk should be considered in future studies...
  54. doi request reprint Daclizumab use in patients with pediatric multiple sclerosis
    Mark P Gorman
    Partners Pediatric Multiple Sclerosis Center, Massachusetts General Hospital, ACC 708, 55 Fruit St, Boston, MA 02114, USA
    Arch Neurol 69:78-81. 2012
    ....
  55. pmc Body size and risk of MS in two cohorts of US women
    Kassandra L Munger
    Department of Nutrition, Harvard School of Public Health, Boston, MA 02115, USA
    Neurology 73:1543-50. 2009
    ..To examine whether obesity during childhood, adolescence, or adulthood is associated with an increased risk of multiple sclerosis (MS)...
  56. pmc Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis
    Riley Bove
    From the UCSF MS Center R B, Department of Neurology, UCSF, Sandler Neurosciences Center, San Francisco, CA Ann Romney Center for Neurologic Diseases C C W, T C, L C, Harvard Medical School, Boston, MA Johns Hopkins Medical Institute K C F, Department of Neurology and Neuroimmunology, Baltimore, MD Partners Multiple Sclerosis Center T C, Department of Neurology, Brigham and Women s Hospital, Brookline Harvard Medical School T C, L C, Boston Channing Division of Network Medicine A A, Brigham and Women s Hospital and Harvard Medical School, Boston and Departments of Nutrition A A, K L M and Epidemiology L C, A A, Harvard T H Chan School of Public Health, Boston, MA
    Neurology 87:1457-1463. 2016
    ..To determine the association between hormone therapy (HT) and physical quality of life (QOL) in postmenopausal women with multiple sclerosis (MS)...
  57. pmc Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk
    Zongqi Xia
    Program in Translational Neuropsychiatric Genomics and Partners Multiple Sclerosis Center, Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Boston, MA
    Ann Neurol 79:178-89. 2016
    ..We discuss the feasibility of large-scale studies of asymptomatic at-risk subjects that leverage modern tools of subject recruitment to execute collaborative projects...
  58. pmc Clinical features of neuromyelitis optica in children: US Network of Pediatric MS Centers report
    Tanuja Chitnis
    From Partners Multiple Sclerosis Center T C, Department of Neurology, Brigham and Women s Hospital, Brookline Partners Pediatric Multiple Sclerosis Center T C, Massachusetts General Hospital for Children, Boston University of Alabama Center for Pediatric Onset Demyelinating Disease J N, Children s Hospital of Alabama, Birmingham the Lourie Center for Pediatric MS, Stony Brook Children s Hospital L K, A B, New York, NY the Department of Neurology E W, J G and the Department of Pediatrics, Benioff Children s Hospital E W, University of California, San Francisco the Departments of Pediatrics T H, C S O, T C C and Neurology J W R, University of Utah, Salt Lake City Mayo Clinic s Pediatric MS Center M R, M P, Rochester, MN Blue Bird Circle Multiple Sclerosis Center T L, Baylor College of Medicine, Houston, TX Boston Children s Hospital M G, L B, MA the Pediatric Multiple Sclerosis Center B W G, Jacobs Neurological Institute, SUNY Buffalo, New York, NY and Pediatric MS Center at Loma Linda University Children s Hospital G A, CA
    Neurology 86:245-52. 2016
    ..To compare clinical features of pediatric neuromyelitis optica (NMO) to other pediatric demyelinating diseases...
  59. pmc The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS
    Riley Bove
    From the Partners Multiple Sclerosis Center R B, M T M, C D C, A C, T J S, D B, E G, B I G, B C H, T C, Department of Neurology, Brigham and Women s Hospital, Brookline Harvard Medical School R B, B I G, B C H, T C, Boston Ann Romney Center for Neurologic Diseases R B, D B, B I G, B C H, T C, Harvard Medical School, Boston and Massachusetts General Hospital Biostatistics Center B C H, Boston, MA
    Neurology 85:1209-13. 2015
    ..To determine whether the 2D:4D ratio (ratio of the second and fourth digit lengths), a proxy for lower prenatal androgen to estrogen ratio, differs in men with and without multiple sclerosis (MS) using a case-control study design...
  60. doi request reprint An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy
    Robert L Carruthers
    Harvard Medical School, USA Partners Multiple Sclerosis Center, Brigham and Women s Hospital, USA
    Mult Scler 20:1381-90. 2014
    ..The lack of prospective trial data comparing certain multiple sclerosis (MS) therapies could be addressed with observational research...
  61. pmc An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2
    Rohit Bakshi
    aDepartment of Neurology bDepartment of Radiology cLaboratory for Neuroimaging Research, Brigham and Women s Hospital dPartners Multiple Sclerosis Center, Harvard Medical School, Boston, Massachusetts, USA
    Neuroreport 25:1156-61. 2014
    ..We describe a new version of the MRDSS, which has been expanded to include cerebral GM and spinal cord involvement. MRDSS2 has concurrent validity with clinical status. ..
  62. ncbi request reprint Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models
    Shinjiro Kaneko
    Division of Neuroscience, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Neurosci 26:9794-804. 2006
    ..Finally, we demonstrate that delayed NAm treatment is also beneficial to EAE models, pointing to the therapeutic potential of NAm as a protective agent for EAE and perhaps MS patients...
  63. ncbi request reprint Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies
    Jaime Imitola
    Center for Neurologic Diseases and Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Arch Neurol 63:25-33. 2006
    ..The molecular pathways leading to structural and functional neurodegeneration and those that prevent regeneration need to be identified in order to design new therapeutic strategies that can halt or even reverse disease progression...
  64. doi request reprint Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity
    Keren Regev
    Ann Romney Center for Neurologic Diseases, Department of Neurology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts
    JAMA Neurol . 2017
    ..MicroRNAs (miRNAs) are promising multiple sclerosis (MS) biomarkers. Establishing the association between miRNAs and magnetic resonance imaging (MRI) measures of disease severity will help define their significance and potential impact...
  65. doi request reprint Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure
    Alicia S Chua
    Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Boston, MA, United States
    Mult Scler Relat Disord 4:598-606. 2015
    ..A brief PRO for MS (BPRO-MS) that combines MS-related psychosocial and quality of life domains can be used to assess overall functioning in mildly disabled MS patients...
  66. doi request reprint Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort
    Dalia L Rotstein
    Partners Multiple Sclerosis Center, Brigham and Women s Hospital, Boston, Massachusetts
    JAMA Neurol 72:152-8. 2015
    ..However, the persistence of NEDA over time and its predictive power for long-term prognosis are unknown...
  67. doi request reprint Sexual disparities in the incidence and course of MS
    Riley Bove
    Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA Harvard Medical School, Boston, MA, USA
    Clin Immunol 149:201-10. 2013
    ..This article summarizes what is known about sexual dimorphism in MS onset and course, as well as potential interactions between sex and other factors influencing MS pathogenesis, incidence and severity. ..
  68. ncbi request reprint Regulation of postsurgical fibrosis by the programmed death-1 inhibitory pathway
    Matthew A Holsti
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    J Immunol 172:5774-81. 2004
    ....
  69. pmc Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis
    Brian C Healy
    Partners MS Center, Harvard Medical School, Brigham and Women s Hospital, 1 Brookline Place, Brookline, MA 02445, USA Biostatistics Center, Massachusetts General Hospital, Boston, MA 02114, USA
    Mult Scler Int 2013:189624. 2013
    ..Relapses or changes in provider did not explain the poor performance of the measures. Short-term changes in the EDSS or FS scores may not be an accurate marker of irreversible change in RRMS...
  70. pmc Prenatal and perinatal factors and risk of multiple sclerosis
    Hannah Gardener
    Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
    Epidemiology 20:611-8. 2009
    ..A potential role of prenatal and perinatal exposures in autoimmunity has been hypothesized, but few studies have examined the relation between various prenatal and perinatal factors and the risk of multiple sclerosis (MS)...
  71. pmc A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis
    Zongqi Xia
    Program in Translational NeuroPsychiatric Genomics, Department of Neurology, Brigham and Women s Hospital, Boston, Massachusetts, United States of America
    PLoS ONE 5:e14169. 2010
    ..We used a candidate gene approach to address whether genetic variants implicated in susceptibility to late onset Alzheimer's Disease (AD) influence brain volume and cognition in MS patients...
  72. doi request reprint Progression rates and sample size estimates for PPMS based on the CLIMB study population
    Kesav Raghavan
    Partners Multiple Sclerosis Center, Brigham and Women s Hospital, USA
    Mult Scler 21:180-8. 2015
    ..The clinical trial design for primary progressive multiple sclerosis (PPMS) requires understanding of disability progression in modern patient cohorts...
  73. doi request reprint Menopause in multiple sclerosis: therapeutic considerations
    Riley Bove
    Department of Neurology, Partners Multiple Sclerosis Center, Brigham and Women s Hospital, 1 Brookline Place West, Suite 225, Brookline, MA, 02445, USA
    J Neurol 261:1257-68. 2014
    ..Finally, we highlight important research gaps, including what effect, if any, the menopausal transition may play on MS disease course as well as the potential modulatory role of hormone replacement therapies. ..
  74. pmc Smoking and disease progression in multiple sclerosis
    Brian C Healy
    Department of Neurology, Partners MS Center, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Arch Neurol 66:858-64. 2009
    ..Although cigarette smokers are at increased risk of developing multiple sclerosis (MS), the effect of smoking on the progression of MS remains uncertain...
  75. ncbi request reprint Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis
    Tanuja Chitnis
    Center for Neurologic Diseases, Brigham and Women s Hospital, Boston, MA 02115, USA
    Immunol Res 28:223-39. 2003
    ..In addition, we will discuss modulation of EAE by altered expression of members of the cytokineregulated Jak/STAT intracellular signaling pathway...
  76. doi request reprint Functional relapses in pediatric multiple sclerosis
    Cristina Fernández Carbonell
    Partners Pediatric Multiple Sclerosis Center, Department of Child Neurology Massachusetts General Hospital, Boston, MA, USA
    J Child Neurol 29:943-6. 2014
    ..Underlying psychiatric issues also need to be addressed. ..
  77. doi request reprint Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy
    Robert L Carruthers
    Department of Neurology, Harvard Medical School, Boston, MA, USA
    Mult Scler 20:757-60. 2014
    ..With this model, one has a means to establish a threshold number of JCV sero-negative natalizumab-associated PML cases at which it is improbable that our understanding of PML risk in JCV sero-negative patients is adequate. ..
  78. doi request reprint The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis
    Riley Bove
    Department of Neurology, Brigham and Women s Hospital, Boston, MA, USA
    Mult Scler 20:520-6. 2014
    ..Finally, we review sex differences in the non-inflammatory facets of MS. We highlight those research gaps that may point to important sex or sex hormone-mediated mechanistic and therapeutic insights...
  79. ncbi request reprint Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis
    Tanuja Chitnis
    Brigham and Women s Hospital, Harvard Medical School, Boston, Mass 02115, USA
    J Allergy Clin Immunol 112:837-49; quiz 850. 2003
    ....
  80. ncbi request reprint Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions
    Kevin C O'Connor
    Laboratory of Molecular Immunology, Harvard Medical School, Center for Neurologic Disease, Brigham and Women s Hospital, Harvard Institutes of Medicine, Rm 780, 77 Avenue Louis Pasteur, Boston, MA 02115, USA
    J Neuroimmunol 136:140-8. 2003
    ..These results indicate that the humoral response in patients with MS does not include moderate- or high-affinity autoantibodies to MBP...
  81. doi request reprint Demographic and clinical characteristics of malignant multiple sclerosis
    T Gholipour
    Partners Multiple Sclerosis Center, Department of Neurology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02445, USA
    Neurology 76:1996-2001. 2011
    ..Malignant status can be transient (TM) or sustained until year 5 (SM). We studied the incidence, predictors, and demographic and clinical characteristics of malignant MS...
  82. ncbi request reprint Challenges in the classification of pediatric multiple sclerosis and future directions
    Anita L Belman
    State University of New York at Stony Brook, Stony Brook, NY 11794
    Neurology 68:S70-4. 2007
    ....
  83. ncbi request reprint Acute disseminated encephalomyelitis
    Silvia Tenembaum
    Department of Pediatric Neurology, National Pediatric Hospital Dr J P Garrahan, Buenos Aires, Argentina
    Neurology 68:S23-36. 2007
    ..An overview of ADEM treatment in children is provided. Finally, the controversies surrounding pediatric MS and ADEM are addressed...